PBM in obstetrics – 3 pillars

- 1. Optimise red blood cell mass before birth
- 2. Minimise blood loss during birth
- 3. Correct severe anaemia with iron infusion & avoid unnecessary RBC transfusions





Results BeQuinT survey: baseline to start from!

- 2.1 Diagnosis and treatment of iron deficiency and anaemia in pregnancy
- 2.2 Immunohematology in the obstetric setting
- 2.3 Identification (and preparation) of patients at increased risk of peripartum bleeding
- 2.4 Management of peripartum bleeding
- 2.5 Screening and management of postpartum iron deficiency and anaemia









2.1 Diagnosis and treatment of iron deficiency and anaemia in pregnancy


Timing full blood count



Whose serum ferritin is tested in the 1st trimester?



Additional blood testing in case of anaemia without iron deficiency





73% of hospitals with systematic **treatment** of **non-anaemic ID** with **oral iron** supplements in 2nd trim.

KCE report 248 – Assessment and screening during pregnancy

Recommendations anaemia	Strength of recommendation	Level of evidence
Offer to test each pregnant woman for anaemia in early pregnancy. In addition to the haemoglobin level, it is also useful to measure the MCV, MCH and MCHC levels. A second examination at the beginning of the 3rd trimester may be indicated ahead of childbirth. [KCE 2004]	Strong	NA (CBR)*
There is no evidence that platelet and leukocyte counts are useful during pregnancy. However, in Belgium, this test is often routinely performed in the laboratory at the time of anaemia detection. [KCE 2004, amended]	NA	NA

^{*} Level of evidence from Australian 2014 guideline: CBR= Consensus based recommendation because insufficient evidence to support recommendation


\$\iff 89\% of hospitals: \frac{full blood count}{} at 1st antenatal visit

\$\Rightrightarrow\$ 49% full blood count at 32-36w





Systematic screening for haemoglobinopathies in pregnant patients




Systematic serum ferritin testing in patients with proven haemoglobinopathy: 81% of hospitals





% hospitals with written protocol







Aim IH in obstetrics: preventing Haemolytic Disease of the Newborn

Haemolytic Disease of the Newborn:


- Estimated incidence of HDN: 3 to 8/100.000 per year
- Before anti-D prophylaxis: responsible for 1% of fetal losses


Red cell antibodies during pregnancy:

- 15% of pregnancies: ABO incompatible
 - 4% HDN
- 1% of pregnancies during first trimester: development of red cell antibodies:
 - 60% not linked to HDN
 - 40% linked to HDN
 - 8% anti-D
 - 32% non-anti-D (mostly anti-K, anti-c, anti-E)














Other:

- together with glucose challenge test at 24 – 25 weeks (3)
- for all RhD negative patients without systematic administration of anti-D Ig (4)
- only for RhD negative mothers with unknown bloodgroup of baby, or known PCR RhD pos (NIPT) (1)

Other timing:

- 24 weeks (1)
- 32 weeks (1)
- 32-36 weeks (1)
- 37 weeks (1)
- between 24-28 weeks, 35 weeks and at birth (1)
- All patients at 32 weeks and all RhDpatients every month (1)







Guidelines

- Systematic testing of ABOD blood group and Indirect Coombs in 1st antenatal visit recommended!
- Repeating Indirect Coombs at 28 weeks: different guidelines!
- References for Belgium:
 - KCE report 248 2015
 - Domus Medica rapport mei 2015
 - VVOG 2023
 - Guide de consultation prénatale 2^e edition Fevr 2022; publié avec CRGOLFB

TO DO: NATIONAL RECOMMENDATIONS BY WORKING GROUP





Risk of immunisation

- Without prophylaxis: 14,7%
- With routine postpartum prophylaxis: 1,6%
- With routine 3rd trimester prophylaxis: 0,5%





Rh D negative blood group with Indirect Coombs positive for anti-D

% of hospitals with written protocol that describes:	
Discussion with the lab whether likely to be passive or preformed allo-antibodies	41%
Women with allogeneic anti-Rh D antibodies do not need (or shouldn't receive) Rh D immunoglobulin	21%

[n=95, multiple answer]





Non-invasive prenatal test (NIPT) for determining fetal Rh D status

% of hospitals with written protocol that describes:

In all Rh D negative pregnant women (who give consent)

15%

[n=95]

Availability is changing!

RIZIV/INAMI diagnostic rules:

- Rh D negative pregnant woman and invasive test
- Rh D negative pregnant woman with anti-D antibodies





Systematic administration of **antenatal** anti-Rh D prophylaxis to Rh D negative women

% of hospitals with written protocol that describes:	
No written protocol on anti-Rh D prophylaxis	51%
At 28 -30 weeks	47%
At 34 weeks	1%
Multiple times antenatal	1%


[n=95, multiple answer]





Antenatal anti-Rh D prophylaxis to Rh D negative women after a sensitising event

% of hospitals with written protocol that describes:	
Administration of antenatal Rh D Ig within 72h of sensitising event	69%
List of potentially sensitising events	47%
Assessment of feto-maternal bleeding volume after a sensitising event (after 20 weeks) to determine the dose of anti-D Ig	62%



Dosing: 1500 IU (300 μg) anti-D profylaxis for 15 mL FMT

[n=95, multiple answer]





After the delivery by Rh D negative women

% of hospitals with written protocol that describes:	
Assessment of feto-maternal bleeding volume to determine the dose of Rh D Ig	57%
Rh D type and Direct Coombs on cord blood or in newborn	66%
Systematic administration of Rh D Ig (at least 500 IU) within 72h of delivery of Rh D positive baby	78%
	[05







Protocol on prophylactic use of Rh D Ig in obstetrics

None of the previously discussed items in a written protocol: 15%







International resources



Blood transfusion in obstetrics. Green-top Guideline No.47. May 2015



SHOT Bite No. 2 Anti-D Ig Administration.

SHOT Anti-D – an aide memoire.

SHOT – How IT systems can support safe practice in anti-D Ig management in pregnancy.





National Blood Authority. Prophylactic use of Rh D immunoglobulin in pregnancy care 2021





National resources | ⇒NEED FOR UNIFORM GUIDELINES!



Clinical guidance paper 2023.

Preventie en behandeling van allo-immunisatie van erytrocyten.

VLAAMSE VERENIGING VOOR OBSTETRIE EN GYNAECOLOGIE vzw.



Guide de consultation prénatale – 2^e edition – fevrier 2022

COLLÈGE ROYAL DES GYNÉCOLOGUES OBSTÉTRICIENS DE LANGUE FRANÇAISE DE BELGIQUE



KCE report 248 – 2015: what are the recommended clinical assesment and screening tests during pregnancy?




Richtlijn zwangerschapsbegeleiding - 2015





Systematic multidisciplinary planning and approach in pregnant patients with suspected Placenta Accreta Spectrum







Written protocol on multidisciplinary management of PPH

(activation of the protocol, gynaecological management, (Point-Of-Care guided) transfusion algorithm, embolisation, etc.)

	% of hospitals
Specific protocol on peripartum haemorrhage	85%
General protocol on massive haemorrhage	15%





Involvement of anaesthesia in early stage of severe peripartum haemorrhage


(even in the absence of haemodynamic instability)

	% of hospitals	
Yes	66%	
No	34%	





Systematic coagulation testing during serious peripartum bleeding



No systematic testing

By viscoelastic tests


By standard lab tests and sometimes

by viscoelastic tests

By standard lab tests

Correction of low fibrinogen < 2 g/L (or ROTEM: FIBTEM A5 < 12 mm)

Which standard coagulation tests? [n=80]







Cell salvage during C-section

	% of hospitals
Never	85%
In patients who refuse transfusion	11%
When RBC are not readily available	5%
Routinely in patients at high risk for PPH	6%






Training on PPH management protocol in past 2 years

	% of hospitals
For obstetricians	55%
For midwifes	61%
For anaesthesiologists	17%
No training	33%






Systematic screening for postpartum iron deficiency and anaemia



Who is systematically screened for postpartum iron deficiency and anaemia?








% of hospitals with written protocol

Screening for postpartum anaemia
Screening for postpartum iron deficiency
Treatment of postpartum anaemia
Treatment of postpartum iron deficiency
Transfusion trigger for red cells in non-bleeding patients in postpartum
Single-unit transfusion of red cells in non-bleeding patients in postpartum







Take home messages

- **1. Anaemia** should be addressed early in pregnancy!
- 2. All obstetric units should have a uniform written protocol on the treatment of IDA!
- 3. Systematic **testing of blood group and antibodies** in first antenatal consult is needed
- 4. Guidelines on monitoring of indirect coombs, antibodies and titers during pregnancy should be uniform!
- 5. Need for written and uniform protocols concerning anti-D prophylaxis
- 6. PCR Foetal Rhesus D in maternal blood is more available





Take home messages

- 7. A multidisciplinary approach and planning should apply to all pregnant women at increased risk for PPH!
- 8. All obstetric units should have a **multidisciplinary protocol on the management of PPH** (including transfusion algoritm)
- 9. Everyone involved (gynaecologists, midwives, anesthesiologists) should be trained on a regular basis!
- 10. All obstetric units should have a **written protocol on the management of postpartum anemia** (to ensure optimal management and improve maternal (functional) outcome)





Goals BeQuinT working group PBM in obstetrics

1) 2024: Webinar(s) PBM in obstetrics

- Diagnosis and treatment of IDA in pregnancy
- Postpartum hemorrhage management
- Immunohematology in pregnancy

2) Recommendations on how to implement PBM in obstetrics

(based on existing international guidelines)





BeQuinT working group PBM in obstetrics



M. Beran (Anaestesiologist, ZOL)

L. Bogaert (clinical biologist, AZ Rivierenland)

Clinicians:

- Obstetricians
 - T. Mesens (ZOL, VVOG)
 - E. Pazzaglia / D. Goldman (CHU Charleroi)
 - S. Hollemaert (CHU Tivoli, CRGOLFB)
 - G. Vandenberghe (UZ Gent)
- Anaesthesiologists
 - L. Balant (CHU Charleroi)
- <u>Haematologist</u>
 M. Colard (Erasme)

Clinical biologists

- G. Bulliard (Croix-Rouge de Belgique)
- L. Moreno (CHU UCL Namur)
- A. Devey (CHU de Liège)



